Literature DB >> 9642529

Drug-induced scleroderma and sclerodermiform conditions.

U F Haustein1, B Haupt.   

Abstract

Entities:  

Mesh:

Year:  1998        PMID: 9642529     DOI: 10.1016/s0738-081x(98)00006-6

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


× No keyword cloud information.
  6 in total

Review 1.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

Review 2.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 3.  Immunotoxicology: role in the safety assessment of drugs.

Authors:  Jacques Descotes
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.

Authors:  Véronique Debien; Arthur Petitdemange; Dorothée Bazin; Carole Ederle; Benoit Nespola; Hamid Merdji; Jérome Olagne; Thierry Martin; Aurélien Guffroy; Carole Pflumio
Journal:  J Scleroderma Relat Disord       Date:  2021-04-13

Review 5.  Drug-induced musculoskeletal disorders.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

6.  Case for diagnosis. Sclerodermiform manifestations of porphyria cutanea tarda secondary to hepatitis C.

Authors:  Juliana de Oliveira Alves Calado; Luan Moura Hortencio Bastos; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.